Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality

Journal of Clinical Oncology

Volumn 34, Issue 28, 2016, Pages 3426-3433

  Fuji, Shigeo ^a   Inoue, Yoshitaka ^a,d   Utsunomiya, Atae ^e   Moriuchi, Yukiyoshi ^f   Uchimaru, Kaoru ^b   Choi, Ilseung ^g   Otsuka, Eiichi ^j   Henzan, Hideho ^h   Kato, Koji ⁱ   Tomoyose, Takeaki ^k   Yamamoto, Hisashi ^c   Kurosawa, Saiko ^a   Matsuoka, Ken Ichi ^l   Yamaguchi, Takuhiro ^m   Fukuda, Takahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TORANOMON HOSPITAL   (Japan)

^d KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^e Imamura Bun in Hospital   (Japan)

^f Sasebo Shiritsu Sogo Hospital   (Japan)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

^h HAMANOMACHI HOSPITAL   (Japan)

ⁱ KYUSHU UNIVERSITY   (Japan)

^j OITA PREFECTURAL HOSPITAL   (Japan)

^k UNIVERSITY OF THE RYUKYUS   (Japan)

^l OKAYAMA UNIVERSITY   (Japan)

^m TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; MOGAMULIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CORTICOSTEROID THERAPY; FEMALE; HUMAN; INCIDENCE; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; SIDE EFFECT; T CELL DEPLETION; T CELL LEUKEMIA; ACUTE DISEASE; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CHEMICALLY INDUCED; FACTUAL DATABASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MIDDLE AGED; MORTALITY; PROCEDURES; SURVIVAL RATE; YOUNG ADULT;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DATABASES, FACTUAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84990068183     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.8250     Document Type: Article

References (37)

1. Ishitsuka K, Tamura K: Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol 15:e517-e526, 2014
2. Tsukasaki K, Hermine O, Bazarbachi A, et al: Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting. J Clin Oncol 27:453-459, 2008
3. Katsuya H, Yamanaka T, Ishitsuka K, et al: Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol 30:1635-1640, 2012
4. Tsukasaki K, Utsunomiya A, Fukuda H, et al: VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25:5458-5464, 2007
5. Yamada Y, Tomonaga M, Fukuda H, et al: A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 113:375-382, 2001
6. Fukushima T, Nomura S, Shimoyama M, et al: Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol 166:739-748, 2014
7. Hishizawa M, Kanda J, Utsunomiya A, et al: Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: A nationwide retrospective study. Blood 116:1369-1376, 2010
8. Yamamoto K, Utsunomiya A, Tobinai K, et al: Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28:1591-1598, 2010
9. Ishida T, Joh T, Uike N, et al: Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. J Clin Oncol 30:837-842, 2012
10. Ishida T, Jo T, Takemoto S, et al: Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: A randomized phase II study. Br J Haematol 169:672-682, 2015
11. Sakaguchi S, Sakaguchi N, Asano M, et al: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151-1164, 1995
12. Michael M, Shimoni A, Nagler A: Regulatory T cells in allogeneic stem cell transplantation. Clin Dev Immunol 2013:608951, 2013
13. Haji S, Kiyasu J, Choi I, et al: Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma. Bone Marrow Transplant 51:432-434, 2015
14. Inoue Y, Fuji S, Tanosaki R, et al: Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality. Bone Marrow Transplant 51:725-727, 2016
15. Przepiorka D, Weisdorf D, Martin P, et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825-828, 1995
16. Murata M, Nakasone H, Kanda J, et al: Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: An analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 19:1183-1189, 2013
17. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
18. Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 79:428-437, 1991
19. Kanda J, Hishizawa M, Utsunomiya A, et al: Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: A retrospective cohort study. Blood 119:2141-2148, 2012
20. Kanda Y: Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48:452-458, 2012
21. Bayer AL, Jones M, Chirinos J, et al: Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT. Blood 113:733-743, 2008
22. Bénard A, Ceredig R, Rolink AG: Regulatory T cells control autoimmunity following syngeneic bone marrow transplantation. Eur J Immunol 36:2324-2335, 2006
23. Anderson BE, McNiff JM, Matte C, et al: Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 104:1565-1573, 2004
24. Komatsu N, Hori S: Full restoration of peripheral Foxp3+ regulatory T cell pool by radioresistant host cells in scurfy bone marrow chimeras. Proc Natl Acad Sci U S A 104:8959-8964, 2007
25. Inoue T, Ikegame K, Kaida K, et al: Host Foxp3+ CD4+ regulatory T cells act as a negative regulator of dendritic cells in the peritransplantation period. J Immunol 196:469-483, 2015
26. Trenado A, Charlotte F, Fisson S, et al: Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 112:1688-1696, 2003
27. Ureshino H, Shindo T, Nishikawa H, et al: Effector regulatory T cells reflect the equilibrium between antitumor immunity and autoimmunity in adult T-cell leukemia. Cancer Immunol Res 10.1158/2326-6066.CIR-15-0303 [epub ahead of print on May 23, 2016]
28. Ni X, Jorgensen JL, Goswami M, et al: Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome. Clin Cancer Res 21:274-285, 2014
29. Ishida T, Ito A, Sato F, et al: Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci 104:647-650, 2013
30. Sugiyama D, Nishikawa H, Maeda Y, et al: Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 110:17945-17950, 2013
31. Matsuoka K, Kim HT, McDonough S, et al: Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest 120:1479-1493, 2010
32. Mohty M, Bacigalupo A, Saliba F, et al: New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity. Drugs 74:1605-1634, 2014
33. Erratum Mohty M, Bacigalupo A, Saliba F, et al: New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity. Drugs 74;2217, 2014
34. Mohty M: Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 21:1387-1394, 2007
35. Taylor PA, Lees CJ, Blazar BR: The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99:3493-3499, 2002
36. Hoffmann P, Eder R, Kunz-Schughart LA, et al: Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 104:895-903, 2004
37. Brunstein CG, Miller JS, Cao Q, et al: Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 117:1061-1070, 2010